ERT and Karel Electronics invests in
Summary
We are excited to announce that ERT —a global leader in respiratory trials and technology, and Karel —a Turkish telecommunications & electronics manufacturing giant, have both recently invested in Inofab Health. Virtualizing clinical trials, Spirohome spirometers and the Spirocloud web platform allows critical lung volume data to be collected from patients in the comfort of their own homes, by-passing limitations imposed by distance and time, and most importantly, those brought on by the current COVID-19 pandemic. We believe that Karel’s manufacturing capacity and infrastructure technologies will help boost the growth of Inofab Health.” We’ve come a long way since the first funds we raised in a series of seed investment rounds led by ACT Venture Partners in April 2017 & January 2018 accelerating the launch of Spirohome®. Removing the burden of travel and costs of clinical visits and empowering patients through the self-management of the disease are just some of the ways in which remote monitoring through Spirocloud serves the field of respiratory healthcare. We believe that with over 550 million people around the world living with chronic lung diseases, the use of remote monitoring platforms for the early detection of exacerbations and prevention of unnecessary hospitalizations is the inevitable option for modern healthcare systems.
Classifications
AskAI Classifications
LabelsLinked Companies
